Tumor therapeutics by design: targeting and activation of death receptors.

[1]  S. Shankar,et al.  Effects of sequential treatments with chemotherapeutic drugs followed by TRAIL on prostate cancer in vitro and in vivo , 2005, The Prostate.

[2]  Wei Wei,et al.  Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo , 2005, Cancer Chemotherapy and Pharmacology.

[3]  Karen Billeci,et al.  Receptor-selective Mutants of Apoptosis-inducing Ligand 2/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Reveal a Greater Contribution of Death Receptor (DR) 5 than DR4 to Apoptosis Signaling* , 2005, Journal of Biological Chemistry.

[4]  M. Peter,et al.  Induction of apoptosis and activation of NF‐κB by CD95 require different signalling thresholds , 2004, EMBO reports.

[5]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[6]  A. Corti,et al.  Crucial Role for Interferon γ in the Synergism between Tumor Vasculature-Targeted Tumor Necrosis Factor α (NGR-TNF) and Doxorubicin , 2004, Cancer Research.

[7]  S. Shankar,et al.  Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms , 2004, The Prostate.

[8]  D. Kabelitz,et al.  Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. , 2004, Immunity.

[9]  D. Lawrence,et al.  Apo2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Chemotherapy to Inhibit Orthotopic Lung Tumor Growth and Improve Survival , 2004, Cancer Research.

[10]  Hong Cheng,et al.  Primary targeting of recombinant Fv-immunotoxin hscFv25-mTNFα against hepatocellular carcinoma , 2004 .

[11]  P. Pour,et al.  The Combination of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL/Apo2L) and Genistein Is Effective in Inhibiting Pancreatic Cancer Growth , 2004, Pancreas.

[12]  S. Shankar,et al.  The sequential treatment with ionizing radiation followed by TRAIL/Apo-2L reduces tumor growth and induces apoptosis of breast tumor xenografts in nude mice. , 2004, International journal of oncology.

[13]  P. Vandenabeele,et al.  Toxic proteins released from mitochondria in cell death , 2004, Oncogene.

[14]  P. Sova,et al.  A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  H. Walczak,et al.  Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 , 2004, International journal of cancer.

[16]  Yasuo Yoshioka,et al.  Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency , 2004 .

[17]  A. Scott,et al.  Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein1 , 2004, The Journal of Immunology.

[18]  T. Sayers,et al.  Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy , 2004, The Journal of experimental medicine.

[19]  M. Rosenblum,et al.  Recombinant single‐chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor , 2004, International journal of cancer.

[20]  R. Longhi,et al.  Coupling Tumor Necrosis Factor-α with αV Integrin Ligands Improves Its Antineoplastic Activity , 2004, Cancer Research.

[21]  S. Lowe,et al.  Control of apoptosis by p53 , 2003, Oncogene.

[22]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[23]  J. Roth,et al.  Current status of gene therapy for lung cancer and head and neck cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  E. Borden,et al.  Suppression of NF-κB Survival Signaling by Nitrosylcobalamin Sensitizes Neoplasms to the Anti-tumor Effects of Apo2L/TRAIL* , 2003, Journal of Biological Chemistry.

[25]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[26]  S. Shankar,et al.  Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. , 2003, Cancer research.

[27]  M. Xiong,et al.  Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  H. Wajant,et al.  Generation of a FasL-based Proapoptotic Fusion Protein Devoid of Systemic Toxicity due to Cell-surface Antigen-restricted Activation* , 2003, Journal of Biological Chemistry.

[29]  S. Ray,et al.  Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. , 2003, Cancer research.

[30]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[31]  A. Eggermont,et al.  Current uses of isolated limb perfusion in the clinic and a model system for new strategies. , 2003, The Lancet. Oncology.

[32]  Dario Neri,et al.  Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. , 2003, Cancer research.

[33]  M. Tykocinski,et al.  CTLA-4 · FasL Induces Alloantigen-Specific Hyporesponsiveness1 , 2003, The Journal of Immunology.

[34]  A. Ashkenazi,et al.  Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. , 2003, Cytokine & growth factor reviews.

[35]  Martin Schenk,et al.  Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. , 2003, Cancer research.

[36]  D. Vaux,et al.  Mammalian mitochondrial IAP binding proteins. , 2003, Biochemical and biophysical research communications.

[37]  Yasuo Yoshioka,et al.  Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity , 2003, Nature Biotechnology.

[38]  S. Larson,et al.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  Jeffrey M. Vinocur,et al.  LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells , 2003, Cancer biology & therapy.

[40]  Pascal Schneider,et al.  Two Adjacent Trimeric Fas Ligands Are Required for Fas Signaling and Formation of a Death-Inducing Signaling Complex , 2003, Molecular and Cellular Biology.

[41]  Klaus Pfizenmaier,et al.  Non-apoptotic Fas signaling. , 2003, Cytokine & growth factor reviews.

[42]  C. Briand,et al.  Insights into the regulatory mechanism for caspase-8 activation. , 2003, Molecular cell.

[43]  D. Green,et al.  A unified model for apical caspase activation. , 2003, Molecular cell.

[44]  E. Bröcker,et al.  Proteasome Inhibition Results in TRAIL Sensitization of Primary Keratinocytes by Removing the Resistance-Mediating Block of Effector Caspase Maturation , 2003, Molecular and Cellular Biology.

[45]  S. Xiao,et al.  A Novel Signaling Mechanism for Soluble CD95 Ligand , 2002, The Journal of Biological Chemistry.

[46]  L. Khawli,et al.  Generation of human interferon gamma and tumor Necrosis factor alpha chimeric TNT-3 fusion proteins. , 2002, Hybridoma and hybridomics.

[47]  M. Xiong,et al.  Long-term tumor-free survival from treatment with the GFP–TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells , 2002, Oncogene.

[48]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[49]  S. Ferrone,et al.  Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. , 2002, Cancer research.

[50]  P. Robbins,et al.  Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  Y. Rustum,et al.  Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. , 2002, Cancer research.

[52]  P. Scheurich,et al.  TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy , 2002, Apoptosis.

[53]  G. Screaton,et al.  Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. , 2002, Cancer cell.

[54]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[55]  S. Libutti,et al.  Induction of permeability across endothelial cell monolayers by tumor necrosis factor (TNF) occurs via a tissue factor-dependent mechanism: relationship between the procoagulant and permeability effects of TNF. , 2002, Blood.

[56]  Angelo Corti,et al.  Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. , 2002, The Journal of clinical investigation.

[57]  Steven A Curley,et al.  Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. , 2002, Cancer research.

[58]  K. Pfizenmaier,et al.  TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor , 2002, Oncogene.

[59]  R. Begent,et al.  In vivo tumor delivery of a recombinant single chain fv :: tumor necrosis factor-alpha fusion protein (vol 13, pg 7, 2002) , 2002 .

[60]  Yigong Shi.  Apoptosome: the cellular engine for the activation of caspase-9. , 2002, Structure.

[61]  R. Coffey,et al.  Vitamin E succinate is a potent novel antineoplastic agent with high selectivity and cooperativity with tumor necrosis factor-related apoptosis-inducing ligand (Apo2 ligand) in vivo. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  S. de Jong,et al.  Fas receptor‐mediated apoptosis: a clinical application? , 2002, The Journal of pathology.

[63]  J. Norris,et al.  Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL , 2002, Cancer Gene Therapy.

[64]  M. Smyth,et al.  Critical Role for Tumor Necrosis Factor–related Apoptosis-inducing Ligand in Immune Surveillance Against Tumor Development , 2002, The Journal of experimental medicine.

[65]  F. Fan,et al.  A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  G. Barber,et al.  Induction of a TRAIL mediated suicide program by interferon alpha in primary effusion lymphoma , 2001, Oncogene.

[67]  A. Almasan,et al.  Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma. , 2001, Blood.

[68]  A. Eggermont,et al.  Isolated Limb Perfusion: The European Experience , 2001 .

[69]  K. Totpal,et al.  Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. , 2001, The Journal of pharmacology and experimental therapeutics.

[70]  T. Griffith,et al.  Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[71]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[72]  Z. Wang,et al.  Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity , 2001, Nature Medicine.

[73]  S. Nagata,et al.  The membrane‐bound but not the soluble form of human Fas ligand is responsible for its inflammatory activity , 2001, European journal of immunology.

[74]  P. Scheurich,et al.  Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative , 2001, Oncogene.

[75]  L. Altucci,et al.  Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL , 2001, Nature Medicine.

[76]  M. Zöller,et al.  Interleukin 2-antibody and tumor necrosis factor-antibody fusion proteins induce different antitumor immune responses in vivo. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  I. Pollack,et al.  Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[78]  H. Koeppen,et al.  Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4 , 2001, The Journal of Immunology.

[79]  S. S. Strom,et al.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions , 2001, Nature Medicine.

[80]  M. Tykocinski,et al.  CTLA-4-Fas ligand functions as a trans signal converter protein in bridging antigen-presenting cells and T cells. , 2001, International immunology.

[81]  E. Nabel,et al.  Extracellular matrix interacts with soluble CD95L: Retention and enhancement of cytotoxicity , 2001, Nature Immunology.

[82]  M. Zöller,et al.  Efficacy of local versus systemic application of antibody-cytokine fusion proteins in tumor therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[83]  M. Smyth,et al.  Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.

[84]  H. Rammensee,et al.  Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. , 2001, Cancer research.

[85]  P. Krammer,et al.  CD95 Ligand-Expressing Tumors Are Rejected in Anti-Tumor TCR Transgenic Perforin Knockout Mice , 2001, The Journal of Immunology.

[86]  A. Eggermont,et al.  TNF is here to stay--revisited. , 2001, Trends in immunology.

[87]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[88]  Peter Scheurich,et al.  p53 upregulates cFLIP, inhibits transcription of NF-κB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells , 2001, Oncogene.

[89]  R. Armitage,et al.  ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. , 2001, Immunity.

[90]  Fulvio Magni,et al.  Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13) , 2000, Nature Biotechnology.

[91]  Y. Tsutsumi,et al.  Human tumor necrosis factor-alpha mutant RGD-V29 (F4614) shows potent antitumor activity and reduced toxicity against human tumor xenografted nude mice. , 2000, Cancer letters.

[92]  M. Rosenblum,et al.  A novel recombinant fusion toxin targeting HER‐2/NEU–over‐expressing cells and containing human tumor necrosis factor , 2000, International journal of cancer.

[93]  A. Almasan,et al.  Apo2 ligand/TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. , 2000, Cancer research.

[94]  J. Tschopp,et al.  The Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptors TRAIL-R1 and TRAIL-R2 Have Distinct Cross-linking Requirements for Initiation of Apoptosis and Are Non-redundant in JNK Activation* , 2000, The Journal of Biological Chemistry.

[95]  J. Norris,et al.  Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  K. Sugimachi,et al.  Expression and Antitumor Effects of TRAIL in Human Cholangiocarcinoma , 2000, Hepatology.

[97]  L. Owen-Schaub,et al.  Fas and Fas ligand interactions in malignant disease. , 2000, International journal of oncology.

[98]  E. Nabel,et al.  Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[99]  F. Zhang,et al.  Adenoviral vector which delivers FasL–GFP fusion protein regulated by the tet-inducible expression system , 2000, Gene Therapy.

[100]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[101]  H. von Bernuth,et al.  An interleukin-2-IgG-Fas ligand fusion protein suppresses delayed-type hypersensitivity in mice by triggering apoptosis in activated T cells as a novel strategy for immunosuppression. , 2000, Transplantation.

[102]  S. Moe,et al.  Opposing Effects of Transmembrane and Soluble FAS Ligand Expression on Inflammation and Tumor Cell Survival , 2000, The Journal of experimental medicine.

[103]  K. Nishioka,et al.  A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. , 2000, International immunology.

[104]  H. Macdonald,et al.  Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells , 2000, European journal of immunology.

[105]  A. Chinnaiyan,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[106]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[107]  F. Batteux,et al.  Expression of Fas ligand improves the effect of IL‐4 in collagen‐induced arthritis , 2000, European journal of immunology.

[108]  A. Strasser,et al.  Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[109]  B. Gliniak,et al.  Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. , 1999, Cancer research.

[110]  J. Dichgans,et al.  Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. , 1999, Biochemical and biophysical research communications.

[111]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[112]  K. Frei,et al.  Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand. , 1999, Human gene therapy.

[113]  A. Fontana,et al.  Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells. , 1999, Journal of immunology.

[114]  A. Sandler,et al.  Overexpression of Fas Ligand Does Not Confer Immune Privilege to a Pancreatic β Tumor Cell Line (βTC-3) , 1999 .

[115]  S. Baekkeskov,et al.  A non-cleavable mutant of Fas ligand does not prevent neutrophilic destruction of islet transplants. , 1999, Transplantation.

[116]  F. Dallegri,et al.  Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.

[117]  P. Lowenstein,et al.  Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity. , 1999, The Journal of general virology.

[118]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[119]  H. Nishimatsu,et al.  Accelerated rejection of Fas ligand-expressing heart grafts. , 1999, Journal of immunology.

[120]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[121]  L. Owen-Schaub,et al.  Fas and Fas Ligand Interactions Suppress Melanoma Lung Metastasis , 1998, The Journal of experimental medicine.

[122]  K. Iwabuchi,et al.  Chemotactic activity of soluble Fas ligand against phagocytes. , 1998, Journal of immunology.

[123]  M. Kronenberg,et al.  Selective Ability of Mouse CD1 to Present Glycolipids: α-Galactosylceramide Specifically Stimulates Vα14+ NK T Lymphocytes , 1998, The Journal of Immunology.

[124]  I. Weissman,et al.  Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. , 1998, Immunity.

[125]  T. Giese,et al.  Spontaneous Development of Plasmacytoid Tumors in Mice with Defective Fas–Fas Ligand Interactions , 1998, The Journal of experimental medicine.

[126]  J. Tschopp,et al.  Conversion of Membrane-bound Fas(CD95) Ligand to Its Soluble Form Is Associated with Downregulation of Its Proapoptotic Activity and Loss of Liver Toxicity , 1998, The Journal of experimental medicine.

[127]  L. Kaer,et al.  Cutting Edge: Critical Role of NK1+ T Cells in IL-12-Induced Immune Responses In Vivo , 1998, The Journal of Immunology.

[128]  T. Ochi,et al.  Membrane Fas Ligand Kills Human Peripheral Blood T Lymphocytes, and Soluble Fas Ligand Blocks the Killing , 1997, The Journal of experimental medicine.

[129]  E. Nabel,et al.  Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[130]  T. Inoue,et al.  Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb. , 1997, International immunology.

[131]  L. Turka,et al.  Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. , 1997, The Journal of clinical investigation.

[132]  D. Hanahan,et al.  Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction , 1997, Nature Medicine.

[133]  D. Vaux,et al.  Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[134]  J. Xiang,et al.  Genetic engineering of a recombinant fusion possessing anti-tumor F(ab')2 and tumor necrosis factor. , 1997, Journal of biotechnology.

[135]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[136]  A. Ishii,et al.  In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. , 1997, International immunology.

[137]  K. Okumura,et al.  Antitumor effect of locally produced CD95 ligand , 1997, Nature Medicine.

[138]  A. Hayday,et al.  A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice , 1996, The Journal of experimental medicine.

[139]  U. Scherf,et al.  Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[140]  G. Butler,et al.  The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.

[141]  C. Stoeckert,et al.  Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice , 1996, Science.

[142]  David Wallach,et al.  Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor–Induced Cell Death , 1996, Cell.

[143]  Matthias Mann,et al.  FLICE, A Novel FADD-Homologous ICE/CED-3–like Protease, Is Recruited to the CD95 (Fas/APO-1) Death-Inducing Signaling Complex , 1996, Cell.

[144]  K. Okumura,et al.  CD95 ligand in graft rejection , 1996, Nature.

[145]  George Kollias,et al.  The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.

[146]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[147]  J. Murray,et al.  An antimelanoma immunotoxin containing recombinant human tumor necrosis factor: tissue disposition, pharmacokinetic, and therapeutic studies in xenograft models , 1995, Cancer Immunology, Immunotherapy.

[148]  P. Scheurich,et al.  Both tumor necrosis factor receptors, TNFR60 and TNFR80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha. , 1995, Blood.

[149]  J. Xiang,et al.  A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor. , 1995, Molecular immunology.

[150]  A. Grzeschiczek,et al.  Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. , 1995, Oncogene.

[151]  Arul M. Chinnaiyan,et al.  FADD, a novel death domain-containing protein, interacts with the death domain of fas and initiates apoptosis , 1995, Cell.

[152]  D. Goeddel,et al.  The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.

[153]  J. Camonis,et al.  A Novel Protein That Interacts with the Death Domain of Fas/APO1 Contains a Sequence Motif Related to the Death Domain (*) , 1995, The Journal of Biological Chemistry.

[154]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[155]  A. Scott,et al.  Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[156]  M. Gately,et al.  Interleukin-12: a cytokine with therapeutic potential in oncology and infectious diseases. , 1994, Therapeutic immunology.

[157]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[158]  S. Gillies,et al.  Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. , 1993, Bioconjugate chemistry.

[159]  G. Volckaert,et al.  Construction and expression of antibody-tumor necrosis factor fusion proteins. , 1991, Molecular immunology.

[160]  G. Volckaert,et al.  Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule. , 1991, Biochimica et biophysica acta.

[161]  B. Kroesen,et al.  Targeted induction of apoptosis for cancer therapy , 2006 .

[162]  P. Scheurich,et al.  Tumor necrosis factor signaling , 2003, Cell Death and Differentiation.

[163]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[164]  Michael Weller,et al.  Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo , 2002, Nature Medicine.

[165]  C. Rüegg,et al.  Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target? , 2002, Endothelium : journal of endothelial cell research.

[166]  R. Begent,et al.  In vivo tumor delivery of a recombinant single-chain Fv::Tumor necrosis factor: A fusion protein , 2002 .

[167]  M. Smyth,et al.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells , 2001, Nature Medicine.

[168]  G. Pietersz,et al.  In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody. , 1998, Journal of drug targeting.

[169]  I. Krantz,et al.  KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene , 1997, Nature Genetics.

[170]  J. Murray,et al.  Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance. , 1991, Cancer communications.

[171]  H. Kosmehl,et al.  This is an author version of the contribution published on: Questa è la versione dell’autore dell’opera: Selective targeted delivery of TNFα to tumor blood vessels , 2022 .